Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Free Dating
Ñompany Maksim-LLC. Ýëåêòðîïðèâîäû. Made and sell.
Popular Articles

Needle Exchange Programs Could Save Texas 'Millions Of Dollars,' Opinion Piece Says
Needle exchange programs (NEPs) "are an inexpensive public health intervention, especially when compared with the social costs of treating individuals with HIV or hepatitis-related chronic liver disease," Maureen Trotter, a pathologist and president of the Taylor-Jones-Haskell County Medical Society, writes in the Abilene Reporter News. She adds that legislation introduced this year in the Texas Legislature "to allow public health departments and organizations to establish disease control programs that provide for the anonymous exchange of used hypodermic needles and syringes for sterile ones, offer education and substance abuse treatment and blood-borne disease testing" failed to come to a floor vote. Trotter further discusses NEPs, citing data on outcomes of NEPs, and writes, "The costs of preventing one case of HIV is estimated between $4,000 and $12,000 via NEPs. The medical cost of treating a person infected with HIV is about $200,000," adding, "These programs, if implemented, could save Texas millions of dollars" (7/12).
new payday loan lenders
Teeny-tiny X-Ray Vision
The tubes that power X-ray machines are shrinking, improving the clarity and detail of their Superman-like vision. A team of nanomaterial scientists, medical physicists, and cancer biologists at the University of North Carolina has developed new lower-cost X-ray tubes packed with sharp-tipped carbon nanotubes for cancer research and treatment.
News of the day
Marking Anorexia With A Brain Protein
Eating disorders are frequently seen as psychological or societal diseases, but do they have an underlying biological cause? A new study shows that the levels of a brain protein differ between healthy and anorexic women.
Oncology

Study Shows GSK's Novel Diabetes Treatment SYNCRIA(R) (albiglutide) Improves Glucose Control And Reduces Weight

New Phase II data presented at the American Diabetes Association 69th Scientific Sessions in New Orleans show that the investigational type 2 diabetes treatment Syncria(R) (albiglutide) significantly reduced blood glucose levels and provided weight loss across weekly, biweekly and monthly dosing. Reducing blood sugar is a key part of managing type 2 diabetes, a disease that affects over 250 million people worldwide. In the study, dose-dependent reductions in A1C - a measure of how well blood sugar is being controlled over time - with albiglutide 30 mg weekly, 50 mg biweekly, and 100 mg monthly were 0.9%, 0.8% and 0.9% respectively (pStudy design The primary objective of the study was to evaluate the dose response of albiglutide for safety and efficacy. The primary efficacy endpoint was change from baseline A1C at week 16 versus placebo across different doses within each schedule (weekly, biweekly, and monthly). The trial was a randomized, multi-center, double-blind, parallel-group study in 356 subjects with type 2 diabetes previously treated with diet and exercise or metformin (mean baseline A1C 8%). Patients received subcutaneous placebo, albiglutide weekly, (4, 15 or 30 mg), biweekly (15, 30 or 50 mg) or monthly (50 or 100 mg), or exenatide (open-label reference arm, in metformin-treated patients) over 16 weeks. About Albiglutide Albiglutide is an investigational biological, injectable form of human GLP-1 - a peptide that acts throughout the body to help maintain normal blood sugar levels and to control appetite. Normally, GLP-1 levels rise during a meal to help the body utilise and control the elevation in blood sugar levels. However, GLP-1 is rapidly degraded, resulting in its short duration of action. In people with type 2 diabetes, GLP-1 secretion in response to a meal is reduced. Albiglutide is the only medication which fuses modified human GLP-1 to human albumin, a protein found in the blood plasma. It is designed to have an extended duration of action and allow for weekly or less-frequent injections. The Phase III programme for albiglutide began with five studies in early 2009 and is expected to last 2-3 years. The 30 mg weekly dose has been selected for the Phase III programme. GlaxoSmithKline one of the world"s leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. Syncria(R) is the registered trademark to be used in the United States. Cautionary statement regarding forward-looking statements Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK"s operations are described under "Risk Factors" in the "Business Review" in the company"s Annual Report on Form 20-F for 2008. GlaxoSmithKline


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009